大血管閉塞性脳卒中に対する血管内血栓除去術後の動脈内テネクテプラーゼ (TNK-FLOW)
The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The primary objective of this study is to determine the safety and feasibility of intra-arterial Tenecteplase in selected patients with persistent post-thrombectomy hypoperfusion on computed tomography perfusion based on symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage producing decline from the initial NIHSS of ≥ 4 points) at 24-36 hours.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- Atrium Health Neurosciences Institute
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patient/legally authorized representative has signed the Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- Functionally independent (modified Rankin scale 0-2) prior to presentation
- Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6
- Clinical syndrome consistent with occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (MCA), presenting within 4.5- to 24-hours of TLKW
- Evidence of ICA, MCA-M1, or MCA-M2 occlusion on baseline computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA). ICA/MCA tandem occlusions may be enrolled
- Alberta Stroke Program Early Computed Tomography Score ≥ 6 on pre-thrombectomy unenhanced CT as determined by treating neurologist or reading radiologist
- Pre-thrombectomy CTP or MRP with core infarction (cerebral blood flow < 30%) < 70 ml, mismatch ratio ≥ 1.8, mismatch volume ≥ 15 ml (completed within 120 minutes of skin puncture for thrombectomy). If skin puncture occurs more than 120 minutes after the pre-thrombectomy CTP, enrollment may proceed at the PI's discretion.
- Endovascular thrombectomy of ICA, MCA-M1 or MCA-M2 occlusion performed according to local standard of care, defined as at least completing the initial diagnostic angiogram
- CTP performed with RAPID AI AngioFlowTM within 30 minutes of thrombectomy completion
- Modified thrombolysis in cerebral infarction (mTICI) 2b-3 revascularization following endovascular thrombectomy (EVT) (or after initial diagnostic angiogram)
- Presence of Tm > 6 lesion on post-EVT CTP of adequate quality for interpretation in the distribution of the symptomatic occlusion
Exclusion Criteria:
- Current participation in another investigational drug or device study
- Known hypersensitivity or allergy to any ingredients of tenecteplase
- Active internal bleeding
- Known bleeding diathesis (e.g., Alzheimer's patients taking lecanemab)
- Systolic blood pressure > 185 mm Hg or diastolic blood pressure > 110 mm Hg after EVT, refractory to medical therapy
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 1.7
- Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)
- Treatment with a thrombolytic within the last 3 months prior to randomization
- Baseline platelet count < 100,000/mcL (results must be available prior to treatment)
- Baseline blood glucose > 400 mg/dL (22.20 mmol/L)
- Baseline blood glucose < 50 mg/dL; needs to be normalized prior to randomization
- Intracranial or intraspinal surgery or trauma within 2 months
- Intracranial malignant neoplasm, arteriovenous malformation, or unsecured aneurysm > 1 cm
- Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months
- History of acute ischemic stroke in the last 90 days
- History of hemorrhagic stroke
- Presumed septic embolus; suspicion of bacterial endocarditis
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed
- Pregnant
- Acute intracranial hemorrhage on pre-thrombectomy imaging or suspected acute intracranial hemorrhage after EVT
- Acute bilateral strokes on initial imaging
- Multiple acute intracranial occlusions (except ICA/MCA) on initial CTA or MRA
- Significant hemispheric mass effect or any amount of midline shift due to acute stroke
- Placement of cervical carotid or intracranial stent during thrombectomy procedure requiring dual antiplatelet therapy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Intra-arterial Tenecteplase
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial tenecteplase post-thrombectomy |
|
プラセボコンパレーター:Intra-arterial Saline
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial saline post-thrombectomy |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participants with Change in Symptomatic Intracranial Hemorrhage
時間枠:Hour 36
|
Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points. |
Hour 36
|
|
Participants with Parenchymal Hematoma Type 1
時間枠:24 Hours
|
Number of participants with parenchymal hematoma type 1 |
24 Hours
|
|
Participants with Parenchymal Hematoma Type 2
時間枠:24 Hours
|
Number of participants with parenchymal hematoma type 2 |
24 Hours
|
|
30-Day Mortality Count
時間枠:Day 30
|
Number of patients expired |
Day 30
|
|
90-Day Mortality Count
時間枠:Day 90
|
Number of patients expired |
Day 90
|
|
Number of Grade 3 Adverse Events
時間枠:Hour 24
|
Total number of grade 3 adverse events |
Hour 24
|
|
Number of Grade 3 Adverse Events
時間枠:Day 5
|
Total number of grade 3 adverse events |
Day 5
|
|
Number of Grade 3 Adverse Events
時間枠:Day 30
|
Total number of grade 3 adverse events |
Day 30
|
|
Number of Grade 3 Adverse Events
時間枠:Day 90
|
Total number of grade 3 adverse events |
Day 90
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of subjects achieving early neurological improvement
時間枠:Hour 24
|
Proportion of subjects achieving early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Hour 24
|
|
Proportion of subjects achieving delayed neurological improvement
時間枠:Day 30, Day 90
|
Proportion of subjects achieving delayed neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Day 30, Day 90
|
|
Ordinal Modified Rankin Scale score
時間枠:Day 90
|
Modified Rankin scale scores range from 0-6. Higher score indicates greater disability. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-2 Points
時間枠:Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-2 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-1 Points
時間枠:Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-1 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-3 Points
時間枠:Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-3 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Change in Infarct Volume
時間枠:Hour 24
|
Change in infarct volume on follow up CT or MRI |
Hour 24
|
|
Barthel Index Score
時間枠:Day 90
|
Number of participants with Barthel Index score ≥ 95. |
Day 90
|
|
Median EuroQol-5-Dimension (EQ-5D) Index
時間枠:Day 90
|
Median EuroQol-5-Dimension (EQ-5D) index has a score range of -0.573 to 1. Higher score indicates better quality score. |
Day 90
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Rahul Karamchandani, MD、Atrium Health Neurosciences Institute
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IRB00121066
- 40010317 (その他の識別子:Genentech, Inc)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。